MUHC Vaccine Study Centre
The MUHC Vaccine Study Centre (VSC) conducts vaccine and epidemiological research. Located in Pierrefonds, Quebec, the VSC has conducted over 200 studies with over 8,000 participants enrolled to date.
Want to make a difference? Call 514-624-7855 or text 514-239-7886.
- About the MUHC Vaccine Study Centre
- Our Team
- Ongoing Clinical Studies
- Completed Studies
- Contact Information
About the MUHC Vaccine Study Centre
Founded in 1991, the MUHC Vaccine Study Centre (VSC) is affiliated with the McGill University Health Centre (MUHC) and the Research Institute of the MUHC (RI-MUHC). The experienced personnel at the VSC conduct vaccine and epidemiological research in collaboration with participants and sponsors. The VSC staff are physicians, nurses and highly trained research personnel, experienced in clinical research and meticulous in their work. They provide a caring, respectful and bilingual environment for study participants.
Our Team
Brian Ward, MD
Jesse Papenburg, MD, M.Sc.
Monica Makarewicz, RN
Ongoing Clinical Studies
A Phase I randomized, observer-blind, placebo-controlled trial of a Haemophilus influenzae serotype A (Hia) glycoconjugate vaccine with alum adjuvant in young adults 18 to 40 years of age.
The first Canadian Controlled Human Infection Model for influenza: A phase 1/2 trial targeting A/H3N2 strain as a foundation for pandemic preparedness.
Phase 1/2, dose-escalation and dose-confirmation clinical trial to establish an influenza Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible influenza A/H3N2 dose administered intranasally to healthy adults that induces mild to moderate symptomatic infection and detection of H3N2 in nasal secretions by culture and/or PCR.
Phase 1/2, dose-escalation and dose-confirmation clinical trial to establish an influenza Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible influenza A/H3N2 dose administered intranasally to healthy adults that induces mild to moderate symptomatic infection and detection of H3N2 in nasal secretions by culture and/or PCR.
Interested in more information about our studies? Please contact us.
Completed Studies
Pfizer - 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Medicago - Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
RI-MUHC - COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases (COVIAAD)
CIHR - COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD)
CIHR - Reinfection in COVID-19 Estimation of Risk: extension
Merck - Efficacy and Safety of MK-1654 in Infants (MK-1654-004)
Moderna - Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children
Merck - Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease
Contact the MUHC Vaccine Study Centre
For more information about the MUHC Vaccine Study Centre and to learn more about participating in studies at the VSC:
Phone: 514-624-7855
Text: 514-239-7886
Email: coordinators.vsc@muhc.mcgill.ca
Visit: 14770 Pierrefonds Blvd., unit 204, Pierrefonds, Quebec H9H 4Y6
Useful Links
- What you need to know about vaccinating your baby
- Quebec Immunization Program
- Immunize Canada
- Understanding vaccines
The MUHC Vaccine Study Centre is proud to collaborate with other vaccine research centres and networks across Canada.
